Literature DB >> 2580892

Enhanced activation of a T cell line specific for acetylcholine receptor (AChR) by using anti-AChR monoclonal antibodies plus receptors.

B C Schalke, W E Klinkert, H Wekerle, D S Dwyer.   

Abstract

Immune complex-mediated regulation of the immune response has been studied by using T cell lines and monoclonal antibodies (MAb), both specific for the acetylcholine receptor (AChR). Rat T lymphocytes bearing the W3/25 phenotype and specific for AChR from Torpedo californica have been propagated in vitro for nearly 1 yr. These T cells proliferate in response to optimal concentrations of AChR presented by irradiated syngeneic thymus cells. At suboptimal concentrations of antigen there is little activation of the T cell line. We report here that the addition of small amounts of anti-AChR MAb produces dramatic stimulation of the T cell lines at suboptimal doses of AChR. Enhanced activation depends on the isotype and not the fine specificity of the MAb that are used. The observed phenomenon is antigen specific, and in fact, the immune complexes may actually suppress the proliferative response of irrelevant T cells to some extent. The MAb plus antigen are rapidly bound to the surface of the antigen-presenting cell, which we have shown is the dendritic cell.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2580892

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  Cellular immune response to the antigen administered as an immune complex in vivo.

Authors:  S Marusić-Galesić; M Marusić; B Pokrić
Journal:  Immunology       Date:  1992-02       Impact factor: 7.397

2.  Highly immunogenic and protective recombinant vaccine candidate expressed in transgenic plants.

Authors:  Daniel Chargelegue; Pascal M W Drake; Patricia Obregon; Alessandra Prada; Neil Fairweather; Julian K-C Ma
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

3.  Cellular immune response to the antigen administered as an immune complex.

Authors:  S Marusić-Galesić; K Pavelić; B Pokrić
Journal:  Immunology       Date:  1991-04       Impact factor: 7.397

4.  Antibodies to acetylcholine receptors in myasthenia gravis. In vitro synthesis by peripheral blood lymphocytes before and after thymectomy.

Authors:  J B Kuks; P C Limburg; H J Oosterhuis; T H The
Journal:  Clin Exp Immunol       Date:  1992-02       Impact factor: 4.330

5.  Autoimmune T lymphocytes in myasthenia gravis. Determination of target epitopes using T lines and recombinant products of the mouse nicotinic acetylcholine receptor gene.

Authors:  A Melms; S Chrestel; B C Schalke; H Wekerle; A Mauron; M Ballivet; T Barkas
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

6.  Inhibitory effects of monoclonal antibodies to a synthetic peptide of influenza haemagglutinin on the processing and presentation of viral antigens to class II-restricted T-cell clones.

Authors:  K H Mills
Journal:  Immunology       Date:  1988-11       Impact factor: 7.397

7.  Protective levels of polysaccharide-specific maternal antibodies may enhance the immune response elicited by pneumococcal conjugates in neonatal and infant mice.

Authors:  Margret Y Richter; Havard Jakobsen; Jean-François Haeuw; Ultan F Power; Ingileif Jonsdottir
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

8.  Subtype cross-reactive, infection-enhancing antibody responses to influenza A viruses.

Authors:  M Tamura; R G Webster; F A Ennis
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

9.  Intra- and intermolecular spreading of autoimmunity involving the nuclear self-antigens La (SS-B) and Ro (SS-A).

Authors:  F Topfer; T Gordon; J McCluskey
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

10.  B-T lymphocyte interactions in experimental autoimmune myasthenia gravis: autoantibody mediated up-regulation of the response of acetylcholine receptor-specific T lymphocytes.

Authors:  Y Zhang; S Tzartos
Journal:  Immunology       Date:  1992-12       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.